These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 8996201

  • 1. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
    Reszka R, Beck P, Fichtner I, Hentschel M, Richter J, Kreuter J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):232-7. PubMed ID: 8996201
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
    Shen LF, Wang X, Wang C, Zhao K, Liu XJ, Shen HJ.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
    [Abstract] [Full Text] [Related]

  • 4. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice.
    Shen LF, Zhang YD, Shen HJ, Zeng S, Wang X, Wang C, Le Y, Shen H.
    Chin Med J (Engl); 2006 Aug 05; 119(15):1287-93. PubMed ID: 16919188
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ, Masin D, Madden TD, Bally MB.
    J Pharmacol Exp Ther; 1997 Apr 05; 281(1):566-73. PubMed ID: 9103545
    [Abstract] [Full Text] [Related]

  • 7. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
    Duan Y, Xu J, Lin Y, Yu H, Gong T, Li Y, Zhang Z.
    J Biomed Mater Res A; 2008 Nov 05; 87(2):515-23. PubMed ID: 18186066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB.
    J Pharmacol Exp Ther; 2000 Jan 05; 292(1):337-45. PubMed ID: 10604968
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
    Cui J, Li C, Wang C, Li Y, Zhang L, Zhang L, Yang H.
    J Pharm Pharmacol; 2008 Dec 05; 60(12):1651-7. PubMed ID: 19000370
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Study on pharmacokinetics of mitoxantrone polycyanoacrylate nanoparticles freeze-dried injection by HPLC column switching technique].
    Zhang ZR, Liao GT, Ye LM.
    Yao Xue Xue Bao; 1995 Nov 05; 30(11):843-7. PubMed ID: 8712010
    [Abstract] [Full Text] [Related]

  • 16. [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].
    Chen T, Hou SX, Sun YY, Zheng Y.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov 05; 37(6):934-7. PubMed ID: 17236598
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C, Cui J, Wang C, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Int J Pharm; 2008 Oct 01; 362(1-2):60-6. PubMed ID: 18598745
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.